752 related articles for article (PubMed ID: 25678132)
1. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
2. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
3. Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis.
Gallucci GM; Trottier J; Hemme C; Assis DN; Boyer JL; Barbier O; Ghonem NS
Hepatol Commun; 2021 Dec; 5(12):2035-2051. PubMed ID: 34558841
[TBL] [Abstract][Full Text] [Related]
4. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
5. Management of cholestatic disease in 2017.
de Vries E; Beuers U
Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
[TBL] [Abstract][Full Text] [Related]
6. Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
Parés A
Dig Dis; 2015; 33 Suppl 2():125-33. PubMed ID: 26642350
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of cholestatic liver diseases].
Gatzen M; Pausch J
Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
[TBL] [Abstract][Full Text] [Related]
8. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol.
Ghonem NS; Auclair AM; Hemme CL; Gallucci GM; de la Rosa Rodriguez R; Boyer JL; Assis DN
Clin Pharmacol Ther; 2020 Dec; 108(6):1213-1223. PubMed ID: 32480421
[TBL] [Abstract][Full Text] [Related]
9. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y
Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624
[TBL] [Abstract][Full Text] [Related]
10. Current pharmacotherapy for cholestatic liver disease.
Carey EJ; Lindor KD
Expert Opin Pharmacother; 2012 Dec; 13(17):2473-84. PubMed ID: 23094715
[TBL] [Abstract][Full Text] [Related]
11. The ascending pathophysiology of cholestatic liver disease.
Jansen PL; Ghallab A; Vartak N; Reif R; Schaap FG; Hampe J; Hengstler JG
Hepatology; 2017 Feb; 65(2):722-738. PubMed ID: 27981592
[TBL] [Abstract][Full Text] [Related]
12. Drug Therapies for Chronic Cholestatic Liver Diseases.
Wagner M; Fickert P
Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
[TBL] [Abstract][Full Text] [Related]
13. Primary biliary cirrhosis and bile acids.
Corpechot C
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
[TBL] [Abstract][Full Text] [Related]
14. New therapies target the toxic consequences of cholestatic liver disease.
Jansen PLM
Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470
[TBL] [Abstract][Full Text] [Related]
15. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
16. Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates.
Poupon R
Dig Dis; 2011; 29(1):85-8. PubMed ID: 21691111
[TBL] [Abstract][Full Text] [Related]
17. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis.
Zollner G; Wagner M; Fickert P; Silbert D; Gumhold J; Zatloukal K; Denk H; Trauner M
Liver Int; 2007 Sep; 27(7):920-9. PubMed ID: 17696930
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.
Wang C; Shi Y; Wang X; Ma H; Liu Q; Gao Y; Niu J
Front Immunol; 2022; 13():940688. PubMed ID: 35880178
[TBL] [Abstract][Full Text] [Related]
19. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Rust C; Beuers U
Clin Rev Allergy Immunol; 2005 Apr; 28(2):135-45. PubMed ID: 15879619
[TBL] [Abstract][Full Text] [Related]
20. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells.
He H; Mennone A; Boyer JL; Cai SY
Hepatology; 2011 Feb; 53(2):548-57. PubMed ID: 21274875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
